
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is facing significant patent expirations in 2026-2028, which poses a risk to their revenue growth. However, the company has a strong pipeline with potential catalysts in various therapeutic areas, including oncology and obesity, and a focus on key growth drivers such as Padcev and Nurtec. With a moderate valuation at 9x forward P/E and a high dividend yield providing downside protection, Pfizer remains an attractive investment opportunity for income-focused investors.
Bears say
Pfizer is facing several headwinds that are contributing to the financial analyst's negative outlook. These include slower growth compared to its peers due to upcoming patent expirations for key drugs such as Vyndaqel and Eliquis, underwhelming performance of its obesity candidates compared to competitors, and inconsistent integration of sustainability considerations into its strategy. These factors, along with concerns about potential drug pricing reform and tariff policy changes, create uncertainty and limit the company's growth potential in the near and mid-term. While Pfizer's dividend is seen as safe, its high payout ratio suggests skepticism from the market on its ability to drive growth and make strategic investments.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares